5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.
第一作者:
Francesco,Del Giudice
第一单位:
Department of Maternal Infant and Urologic Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy. francesco.delgiudice@uniroma1.it.
作者:
主题词
男(雄)性(Male);人类(Humans);美国(United States);5-α还原酶抑制剂(5-alpha Reductase Inhibitors);前列腺增生(Prostatic Hyperplasia);危险(Risk);保险(Insurance);膀胱肿瘤(Urinary Bladder Neoplasms)
DOI
10.1007/s00345-023-04551-4
PMID
37548746
发布时间
2024-01-29
- 浏览1

World journal of urology
2783-2791页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文